Eli Lilly to double its manufacturing capacity for Mounjaro as it faces financial headwinds going into 2023 — report

Eli Lilly is facing several financial headwinds going into next year, spurred by the drying up of Covid-19 antibody sales and supply constraints, according to a report from SVB Securities by three of its analysts who visited Eli Lilly’s headquarters in Indianapolis last week.

An anticipated “stepdown” in Covid-19 antibody sales, after about $2 billion in recent sales, due to a lack of protection against the newer variants, as well as other speedbumps like Alimta generics, pressure from inflation and incremental costs for manufacturing were cited as potential headwinds.

Potential tailwinds for the pharma include the Type 2 diabetes drug Mounjaro, which is not expected to have “payer access levels” comparable to Trulicity until later next year.